Log In Get Started
Press Releases May 5, 2026 04:05 PM

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference

Alamar Biosciences to Present at BofA Securities 2026 Healthcare Conference

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
ALMR

Alamar Biosciences, a leader in Precision Proteomics, announced it will present at the BofA Securities 2026 Healthcare Conference, showcasing its NULISA technology and ARGO HT System aimed at early disease detection through biomarker analysis.

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
ALMR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alamar Biosciences will present at a major healthcare conference, providing exposure to investors and industry peers.
  • The company focuses on Precision Proteomics using proprietary NULISA technology and the ARGO HT System for ultra-sensitive biomarker detection.
  • Their platform is designed to improve early disease detection by overcoming limitations of existing technologies, impacting healthcare diagnostics and biotech sectors.

FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will be participating in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada.

Alamar Biosciences’ management is scheduled to present on Tuesday, May 12, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the “Investors” section of the company website at investors.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar is a life sciences company dedicated to powering Precision Proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar’s platform is designed to detect biomarkers with ultra-high sensitivity and address key limitations of existing technologies, helping researchers unlock the full spectrum of protein biomarkers across disease states.

Investor contact:

[email protected]

Media contact:

[email protected]


Risks

  • The market reaction to the conference presentation may be limited if no new product updates or financial data are disclosed.
  • As a biotech firm early in its development stage, there is inherent scientific and regulatory risk associated with the success of their proteomics platform.
  • Dependence on adoption by researchers and healthcare providers introduces uncertainty in commercial scalability and revenue generation.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026